Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae Campylobacter jejuni ATCC 59 ATCC 785 ATCC 91 ATCC 91 ATCC 9619 NCTC 868 1 ATCC 560 Version number Strain/page Changes Cells containing a change or an addition from v.0 are marked blue..1, 01-0-11 First page Typo corrected for Campylobacter jejuni. The correct ATCC number is 560. ATCC 59 Typo corrected on ceftaroline range. 0.0.0.1 changed to 0.0-0.1. Version number Strain/page Changes Cells containing a change or an addition from v.1 are marked yellow. ATCC 59 QC ranges updated : Cefalexin (zone). QC ranges added: Ceftaroline ( and zone). ATCC 91 QC ranges added: Ceftaroline ( and zone)..0, 01-01-01 ATCC 9619 Clarification regarding differentiation between haemolysis and growth. QC ranges added: Ceftaroline (). NCTC 868 QC ranges added: Ceftaroline (range to be established). ATCC 560 New QC strain. All ranges new. 1 NCTC 868 is susceptible to beta-lactam antibiotics and often easier to read on MH-F than the commonly recommended ATCC 97 showing variable inhibition zones for beta-lactam antibiotics due to PBP mutations. Updated by EUCAST.
Escherichia coli ATCC 59 (NCTC 11, CIP 76., DSM 110, CCUG 1760, CECT ) Mueller-Hinton agar, McFarland 0.5, air, 5±1ºC, 18±h. Read zone edges as the point showing no growth viewed from the back of the plate against a dark background illuminated with reflected light. Target 1 Range (µg) Amikacin 1-0.5-0 19-6 Amoxicillin -8 - - - Amoxicillin-clavulanic acid / /1-8/ 0-10 1 18-5 Ampicillin -8 10 19 16-5 Ampicillin-sulbactam / /1-8/ 10-10 19-5 Aztreonam 0.1 0.06-0.5 0 8-6 Cefadroxil - - 0 17 1-0 Cefalexin 8-16 0 18 15-1 Cefepime 0.0-0.06 0.015-0.1 0 1-7 Cefixime 0.5 0.5-1 5 5-7 Cefotaxime 0.06 0.0-0.1 5 8 5-1 Cefoxitin -8 0 6-9 Cefpodoxime 0.5 0.5-1 10 6-8 Ceftaroline 0.06 0.0-0.1 5 7-0 Ceftazidime 0.1-0.5 0.06-0.5 10 6-9 Ceftibuten 0.5 0.1-0.5 0 1 7-5 Ceftriaxone 0.06 0.0-0.1 0 9-5 Cefuroxime -8 0 0-6 Chloramphenicol -8 0 1-7 Ciprofloxacin 0.008 0.00-0.015 5 5 0-0 Colistin 0.5-1 0.5- - - - Doripenem 0.0 0.015-0.06 10 1 7-5 Ertapenem 0.008 0.00-0.015 10 9-6 Fosfomycin 6 1 0.5- - - - Gentamicin 0.5 0.5-1 10 19-6 Imipenem 0.1 0.06-0.5 10 9 6- Levofloxacin 0.015-0.0 0.008-0.06 5 9-7 Mecillinam 0.06-0.1 0.0-0.5 10 7-0 Meropenem 0.015-0.0 0.008-0.06 10 1 8- Moxifloxacin 0.015-0.0 0.008-0.06 5 8-5 Nalidixic acid 1-0 5-8 Netilmicin - 0.5-1 10 1 18- Nitrofurantoin 8-16 100 0 17- Norfloxacin 0.06 0.0-0.1 10 8-5 Ofloxacin 0.0-0.06 0.015-0.1 5 1 9- Piperacillin 1-0 1-7 Piperacillin-tazobactam / 1/-/ 0-6 1-7 Ticarcillin 8-16 75 7-0 Ticarcillin-clavulanic acid 8/ /-16/ 75-10 7-0 Tigecycline 6 0.1 0.0-0.5 15 0-7 Tobramycin 0.5 0.5-1 10 18-6 Trimethoprim 1 0.5-5 5 1-8 Trimethoprim-sulfamethoxazole 0.5/9.5-1.5-.75 6-9 From International Standards Organisation, ISO 0776-1: 006, except ranges in bold/italics established by EUCAST. From Clinical and Laboratory Standards Institute, M100-S: :, 01, except ranges in bold/italics established by EUCAST. All ranges have been validated by EUCAST. Ranges and targets are valid for a :1 ratio of beta-lactam agent to beta-lactamase inhibitor. EUCAST is currently collecting data to establish control ranges with fixed beta-lactamase inhibitor concentrations, in accordance with EUCAST breakpoints. 5 Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. 6 For test conditions, see Clinical and Laboratory Standards Institute, M100-S: :, 01.
Pseudomonas aeruginosa ATCC 785 (NCTC 190, CIP 76.110, DSM 1117, CCUG 17619, CECT 108) Mueller-Hinton agar, McFarland 0.5, air, 5±1ºC, 18±h. Read zone edges as the point showing no growth viewed from the back of the plate against a dark background illuminated with reflected light. Target 1 Range (µg) Amikacin 1-0 18-6 Aztreonam -8 0 6-9 Cefepime 1-0.5-0 7-0 Ceftazidime 1-10 1-7 Ciprofloxacin 0.5 0.5-1 5 9 5- Colistin 1-0.5- - - - Doripenem 0.5 0.1-0.5 10 8-5 Fosfomycin -8 - - - Gentamicin 1 0.5-10 0 17- Imipenem 1-10 0-8 Levofloxacin 1-0.5-5 19-6 Meropenem 0.5 0.5-1 10 0 7- Netilmicin 0.5-8 10 18 15-1 Piperacillin - 1-8 - - - Piperacillin-tazobactam -/ 1/-8/ 0-6 6-9 Ticarcillin 16 8- - - - Ticarcillin-clavulanic acid 16/ 8/-/ 75-10 0-8 Tobramycin 0.5 0.5-1 10 0-6 From International Standards Organisation, ISO 0776-1: 006. From Clinical and Laboratory Standards Institute, M100-S: :, 01, except ranges in bold/italics established by EUCAST. All ranges have been validated by EUCAST. For test conditions, see Clinical and Laboratory Standards Institute, M100-S: :, 01.
Staphylococcus aureus ATCC 91* (NCTC 197, CIP 109, DSM 569, CCUG 15915, CECT 79) * β-lactamase-producing strain (weak) Mueller-Hinton agar, McFarland 0.5, air, 5±1ºC, 18±h. Read zone edges as the point showing no growth viewed from the back of the plate against a dark background illuminated with reflected light. Target 1 Range (µg) Amikacin 1-0 1 18- Ampicillin - - 18 15-1 Azithromycin 1 0.5- - - - Benzylpenicillin 0.5-1 0.5-1 unit 15 1-18 Cefoxitin 1-0 7-0 Ceftaroline 0.5 0.1-0.5 5 7-0 Chloramphenicol -8-16 0 0-8 Ciprofloxacin 0.5 0.1-0.5 5 1-7 Clarithromycin 0.5 0.1-0.5 - - - Clindamycin 0.1 0.06-0.5 6-9 Daptomycin 5 0.5-0.5 0.1-1 - - - Doxycycline 0.5 0.1-0.5 - - - Erythromycin 0.5 0.5-1 15 6-9 Fosfomycin 5 1-0.5- - - - Fusidic acid 0.1 0.06-0.5 10 9 6- Gentamicin 0.5-0.5 0.1-1 10 19-5 Levofloxacin 0.1-0.5 0.06-0.5 5 6-9 Linezolid 1-10 1-7 Minocycline 0.1-0.5 0.06-0.5 0 6-9 Moxifloxacin 0.0-0.06 0.015-0.1 5 8 5-1 Mupirocin 0.1 0.06-0.5 00 1-7 Netilmicin 0.5-10 0-6 Nitrofurantoin 16 8-100 0 17- Norfloxacin 1 0.5-10 1 18- Ofloxacin 0.5-0.5 0.1-1 5 1-7 Quinupristin-dalfopristin 0.5 0.5-1 15 1-7 Rifampicin 0.008 0.00-0.015 5 0-6 Teicoplanin 0.5 0.5-1 - - - Telavancin 0.5-0.5 0.1-1 - - - Tetracycline 0.5-0.5 0.1-1 0 7-1 Tigecycline 5 0.06-0.1 0.0-0.5 15 19-5 Tobramycin 0.5-0.5 0.1-1 10 0-6 Trimethoprim 1-5 5-8 Trimethoprim-sulfamethoxazole 0.5/9.5-1.5-.75 9 6- Vancomycin 1 0.5- - - - From International Standards Organisation, ISO 0776-1: 006. From Clinical and Laboratory Standards Institute, M100-S: :, 01. 5 For test conditions, see Clinical and Laboratory Standards Institute, M100-S: :, 01.
Enterococcus faecalis ATCC 91 (NCTC 1697, CIP 101, DSM 570, CCUG 9997, CECT 795) Mueller-Hinton agar, McFarland 0.5, air, 5±1ºC, 18±h. Read zone edges as the point showing no growth viewed from the back of the plate against a dark background illuminated with reflected light. Target 1 Range (µg) Ampicillin 1 0.5-18 15-1 Gentamicin 8-16 0 15 1-18 Imipenem 1 0.5-10 7-0 Linezolid 1-10 19-5 Nitrofurantoin 8-16 100 1 18- Quinupristin-dalfopristin -8 15 1 11-17 Teicoplanin 0.5 0.5-1 5 0 18 15-1 Tigecycline 6 0.06 0.0-0.1 15 0-6 Trimethoprim 0.5 0.1-0.5 5 5 8 - Trimethoprim-sulfamethoxazole 0.5/9.5-1.5-.75 0 6- Vancomycin 1-5 1 10-16 From International Standards Organisation, ISO 0776-1: 006. Screening disk for high-level aminoglycoside-resistance in enterococci. 5 From Clinical and Laboratory Standards Institute, M100-S: :, 01. 6 For test conditions, see Clinical and Laboratory Standards Institute, M100-S: :, 01.
Streptococcus pneumoniae ATCC 9619*/** (NCTC 1977, CIP 100, DSM 11967, CCUG 68) * Penicillin-intermediate strain ** Zone edges for S. pneumoniae on MH-F are often accompanied by α-haemolysis. Read inhibition of growth and not inhibition of haemolysis. Tilt the plate to easier differentiate between haemolysis and growth. There is usually growth in the whole area of α-haemolysis but on some MH-F media, there is additional α-haemolysis without growth. Mueller-Hinton agar + 5% horse blood and 0 mg/l β-nad, McFarland 0.5, 5% CO, 5±1ºC, 18±h. Read zone edges as the point showing no growth viewed from the front of the plate with the lid removed and with reflected light. Target 1 Range (µg) Amoxicillin 0.06 0.0-0.1 - - - Ampicillin 0.1 0.06-0.5 8 5-1 Azithromycin 0.1 0.06-0.5 - - - Benzylpenicillin 0.5 0.5-1 1 unit 19 16- Cefaclor 1-0 8 5-1 Cefepime 0.06-0.1 0.0-0.5 0 1-7 Cefotaxime 0.06 0.0-0.1 5 1 8- Cefpodoxime 0.06 0.0-0.1 10 9-5 Ceftaroline 0.015 0.008-0.0 5 IP IP Ceftriaxone 0.06 0.0-0.1 0 5-8 Cefuroxime 0.5 0.5-1 0 1 8- Chloramphenicol -8 0 7-0 Ciprofloxacin - - 5 5-8 Clarithromycin 0.06 0.0-0.1 - - - Clindamycin 0.06 0.0-0.1 5-8 Daptomycin 5 0.1-0.5 0.06-0.5 - - - Doripenem 0.06 0.0-0.1 10 1-7 Doxycycline 0.0-0.06 0.015-0.1 - - - Ertapenem 0.06-0.1 0.0-0.5 10 1 8- Erythromycin 0.06 0.0-0.1 15 9 6- Imipenem 0.06 0.0-0.1 10 8 - Levofloxacin 1 0.5-5 1-7 Linezolid 0.5-1 0.5-10 6-9 Meropenem 0.1 0.06-0.5 10 0-8 Minocycline - - 0 8 5-1 Moxifloxacin 0.1 0.06-0.5 5 7-0 Nitrofurantoin 8-16 100 8 5-1 Norfloxacin -8 10 1 18- Ofloxacin 1-5 1 18- Oxacillin - - 1 11 8-1 Rifampicin 0.0 0.015-0.06 5 9 6- Teicoplanin - - 0 1 18- Telithromycin 0.008-0.015 0.00-0.0 15 0 7- Tetracycline 0.1-0.5 0.06-0.5 0 1 8- Tigecycline 5 0.0-0.06 0.015-0.1 15 7-0 Trimethoprim-sulfamethoxazole 0.5/.75-0.5/9.5 0.1/.-1/19 1.5-.75 0-6 Vancomycin 0.5 0.1-0.5 5 0 17- From International Standards Organisation, ISO 0776-1: 006. Clinical and Laboratory Standards Institute, M100-S: :, 01. 5 For test conditions, see Clinical and Laboratory Standards Institute, M100-S: :, 01. IP = In Preparation
Haemophilus influenzae NCTC 868 (CIP 5.9, CCUG 96) Mueller-Hinton agar + 5% horse blood and 0 mg/l β-nad, McFarland 0.5, 5% CO, 5±1ºC, 18±h. Read zone edges as the point showing no growth viewed from the front of the plate with the lid removed and with reflected light. (µg) Target Range Target 1 Range Amoxicillin-clavulanic acid IP IP -1 0 17- Ampicillin IP IP 19-5 Benzylpenicillin IP IP 1 unit 16 1-19 Cefaclor IP IP 0 7-0 Cefepime IP IP 0 9-5 Cefixime IP IP 5 0 7- Cefotaxime IP IP 5 9-5 Cefpodoxime IP IP 10 1 8- Ceftaroline IP IP 5 IP IP Ceftibuten IP IP 0 0-6 Ceftriaxone IP IP 0 7-1 Cefuroxime IP IP 0 8 5-1 Chloramphenicol IP IP 0 0-8 Ciprofloxacin IP IP 5 5 1-9 Doripenem IP IP 10 9 6- Ertapenem IP IP 10 0 7- Erythromycin IP IP 15 15 1-18 Imipenem IP IP 10 8 5-1 Levofloxacin IP IP 5 5-8 Meropenem IP IP 10 1 8- Minocycline IP IP 0 0 7- Moxifloxacin IP IP 5 9-5 Nalidixic acid IP IP 0 0 7- Ofloxacin IP IP 5 0-6 Rifampicin IP IP 5 0-6 Telithromycin IP IP 15 18 15-1 Tetracycline IP IP 0 1 8- Trimethoprim-sulfamethoxazole IP IP 1.5-.75 0 6- IP = In Preparation
Campylobacter jejuni ATCC 560 (NCTC 1151, CIP 70, DSM 688, CCUG 118) Mueller-Hinton agar + 5% horse blood and 0 mg/l β-nad, McFarland 0.5, microaerobic environment, 1±1ºC, h. Read zone edges as the point showing no growth viewed from the front of the plate with the lid removed and with reflected light. The MH-F plates should be dried prior to inoculation to reduce swarming (at 0-5 C over night or at 5 C, with the lid removed, for 15 min). (µg) Target Range Target 1 Range Ciprofloxacin IP IP 5 8 - Erythromycin IP IP 15 1 7-5 Tetracycline IP IP 0 0-8 IP = In Preparation